Open-Label Phase 1 Futility Studies of Salsalate and Young Plasma in Progressive Supranuclear Palsy.

Lawren VandeVredeMarian L DaleScott FieldsMegan FrankEmma HareHilary W HeuerKellie KeithMary KoestlerPeter A LjubenkovDana McDermottNoelle OhanesianJennifer RichardsJulio C RojasElisabeth H ThijssenChristine WalshPing WangAmy WolfJoseph F QuinnRichard TsaiAdam L Boxer

Published in: Movement disorders clinical practice (2020)

Neither salsalate nor young plasma had a detectable effect on disease progression in PSP-RS. Focused open-label clinical trials incorporating historical clinical, neuropsychological, fluid, and imaging biomarkers provide useful preliminary data about the promise of novel PSP-directed therapies.

Keyphrases

open label
clinical trial
phase ii
phase iii
phase ii study
big data
middle aged
high resolution
study protocol
multiple sclerosis
electronic health record
mild cognitive impairment
randomized controlled trial
double blind
case control
radiation therapy
fluorescence imaging